^
    1d
    ARTISAN: Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) (clinicaltrials.gov)
    P1, N=80, Recruiting, ARTBIO Inc. | Trial completion date: Sep 2033 --> Nov 2028
    Trial completion date
    |
    AB001
    6d
    Cytotoxicity and cell cycle changes in prostate cancer cells with differing PSMA expression and p53 status after treatment with PSMA-targeting radioligand [212Pb]Pb-AB001. (PubMed, Sci Rep)
    Total cell-bound activity, rather than added activity, better predicted radiotoxicity in both TP53-wild-type and TP53-null cell lines, indicating that its therapeutic effect is primarily governed by PSMA-mediated uptake rather than p53 status. These results support the therapeutic potential of [212Pb]Pb-AB001 across cells with varying TP53 status and suggest that combining [212Pb]Pb-AB001 with DNA repair or checkpoint inhibitors may enhance treatment efficacy.
    Journal
    |
    TP53 (Tumor protein P53) • FOLH1 (Folate hydrolase 1)
    |
    TP53 wild-type • FOLH1 expression
    |
    AB001
    8d
    Clinical Experience with Targeted Alpha-Emitter Peptide Receptor Radionuclide Therapy (α-PRRT) for Somatostatin Receptor-Positive Neuroendocrine Tumors. (PubMed, Pharmaceuticals (Basel))
    Early results support α-PRRT as a potential first- or second-line therapeutic option. Ongoing phase III trials will be critical to confirm its long-term safety, survival outcomes, and role in routine clinical practice.
    Review • Journal
    |
    SSTR (Somatostatin Receptor)
    |
    SSTR positive
    |
    VMT-𝛼-NET
    9d
    ATLAS: Actinium Therapy for Late-stage Aggressive Sarcomas (clinicaltrials.gov)
    P1, N=26, Recruiting, Ratio Therapeutics, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    14d
    First-in-human study of a thorium-227-labeled mesothelin-targeting antibody-chelator conjugate (MSLN-TTC), in patients with malignant mesothelioma and other solid tumors. (PubMed, ESMO Open)
    MSLN-TTC showed good tolerability, but the maximum tolerated dose could not be determined due to discontinuations after antidrug antibody formation. Stable disease was observed in 12 out of 36 patients.
    P1 data • Journal • First-in-human
    |
    MSLN (Mesothelin)
    |
    thorium (227Th) anetumab corixetan (BAY 2287411)
    14d
    Rad2Nivo: Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=39, Active, not recruiting, University of Utah | Trial primary completion date: Jul 2025 --> Feb 2025
    Trial primary completion date • Tumor mutational burden
    |
    Opdivo (nivolumab) • Xofigo (radium Ra-223 dichloride)
    22d
    A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours (clinicaltrials.gov)
    P1, N=70, Recruiting, AstraZeneca | N=169 --> 70 | Trial completion date: Dec 2027 --> May 2028 | Trial primary completion date: Dec 2026 --> May 2028
    Enrollment change • Trial completion date • Trial primary completion date • First-in-human
    22d
    MED20-165: Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
    P1, N=12, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jan 2026 --> Jan 2027 | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial completion date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule)
    |
    Iomab-B (I-131-apamistamab)
    23d
    ARTISAN: Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) (clinicaltrials.gov)
    P1, N=80, Recruiting, ARTBIO Inc. | Trial primary completion date: Sep 2033 --> Nov 2027
    Trial primary completion date
    |
    AB001
    24d
    CR108817: A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer (clinicaltrials.gov)
    P1, N=177, Recruiting, Janssen Research & Development, LLC | Trial completion date: Nov 2028 --> Oct 2027 | Trial primary completion date: Nov 2028 --> Oct 2027
    Trial completion date • Trial primary completion date
    |
    JNJ-6420 • pasritamig (JNJ-8343)
    1m
    PSMAcTION: Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy (clinicaltrials.gov)
    P2/3, N=432, Recruiting, Novartis Pharmaceuticals | Trial completion date: Apr 2033 --> Jul 2033 | Trial primary completion date: Mar 2028 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    225Ac-vipivotide tetraxetan (AAA817)
    1m
    A Phase 1 Study of [225Ac]-FPI-1434 Injection (clinicaltrials.gov)
    P1, N=253, Active, not recruiting, Fusion Pharmaceuticals Inc. | Recruiting --> Active, not recruiting | Phase classification: P1/2 --> P1 | Trial completion date: Jun 2026 --> Dec 2025 | Trial primary completion date: Apr 2026 --> Dec 2025
    Enrollment closed • Phase classification • Trial completion date • Trial primary completion date
    |
    IGF1 (Insulin-like growth factor 1)
    |
    HER-2 negative
    |
    FPI-1434